Market Overview

Canaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For Shares

Canaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For Shares

CARDIOME PHARMA CORP (NASDAQ: CRME) announced Tuesday it has agreed to divest its Canadian business to Cipher Pharmaceuticals for the U.S. dollar equivalent of $19.7 million. 

The Analyst

Canaccord Genuity's Dewey Steadman maintains a Buy rating on Cardiome's stock with an unchanged $5 price target.

The Thesis

Cardiome's sale of its Canadian business includes on-market Brinavess and Aggrastat and is complemented by the Xydalba and Trevyent pipeline projects, Steadman said in a Tuesday note. (See the analyst's track record here.) 

Cardiome will form a new company named Correvio and will net the $19 million in cash, which would boost its estimated cash balance to around $40 million, the analyst said. The cash on hand should prove to be sufficient to finance the pharma company's operations through at least 2019, if not longer, he said. 

The divestiture is also an "attractive way" for Cardiome to finance its near-term business development without "sacrificing much upside," given the company's approximately $77,000 in revenue in 2017, the analyst said.

In return, Cipher likely accepted the transaction as it includes Cardiome's roughly $232.5 million in Canadian tax losses that Cardiome would never fully utilize itself.

Cardiome's deal is viewed favorably within the "often-overlooked" specialty pharmaceutical market outside of the U.S, Steadman said. 

Price Action

Shares of Cardiome Pharma were up 3.35 percent at the close Wednesday. 

Related Links:

27 Stocks Moving In Wednesday's Mid-Day Session

Mid-Day Market Update: Crude Oil Up 2.5%; General Mills Shares Plunge

Latest Ratings for CRME

Nov 2017MaintainsBuy
Jul 2017AssumesBuy
Dec 2016Initiates Coverage OnOutperform

View More Analyst Ratings for CRME
View the Latest Analyst Ratings

Posted-In: Aggrastat Brinavess Canaccord Genuity CanadaAnalyst Color Price Target Reiteration Analyst Ratings Best of Benzinga


Related Articles (CRME)

View Comments and Join the Discussion!

Latest Ratings

LOWRBC CapitalMaintains129.0
MARRBC CapitalMaintains148.0
CRLSunTrust Robinson HumphreyMaintains162.0
CFRSunTrust Robinson HumphreyMaintains105.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Previewing The Tech Sector As Earnings Season Looms

Esports Continue To Become More Mainstream And a Bigger Part Of The Gaming Industry